Advertisement

Topics

Sal. Oppenheim jr. & Cie. KGaA Company Profile

04:09 EDT 23rd September 2018 | BioPortfolio

Innovation and tradition – we have always succeeded in combining the two. Since the company‘s founding in 1789, the Cologne private bankers of Sal. Oppenheim have always been a motor for progress - open to new developments in industry and business, open to art and culture, and, of course, always open to new financial models. Sal. Oppenheim today is one of Europe‘s leading private banks. The focus of our activities is asset management and investment banking. Whether you are a wealthy private client or a demanding corporate customer, we completely adapt to your individual needs. Our independence guarantees the responsibility of our actions. It is the basis for our decisions and the foundation of our success: Sal. Oppenheim currently manages and administers € 123 billion of assets. Around 3.160 emloyees work at more than 20 sites in Germany and Europe. Our company‘s employees share one goal: your financial success

Location

Unter Sachsenhausen 4
Cologne
Berlin
D-50667
Germany

Contact

Phone: 49 (0)221 / 145-01
Fax: 49 (0)221 / 145-1512
Email: info@oppenheim.de


News Articles [236 Associated News Articles listed on BioPortfolio]

Appointments: Changes At Merck KGaA, Servier, Unum and Aduro

The latest biopharma industry appointments include a new chief patient officer at Servier, executives at Merck KGaA, Unum and Aduro...  

Post-Rebif, Merck KGaA Keeps Faith With MS Therapies

CEO Stefan Oschmann is sticking to his previous forecast of annual peak sales of €500-700m for Mavenclad, excluding the US...   

Merck KGaA Achieves 2017 Targets

NewsMerck KGaA, Darmstadt, Germany met its targets for 2017 and achieved importan tstrategic successes with the approvals of two new medicines.Contributed Author:&nbs

DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius kündigt Übernahmevereinbarung mit Akorn (deutsch)

Fresenius SE & Co. KGaA: Fresenius kündigt Übernahmevereinbarung mit Akorn DGAP-Ad-hoc: Fresenius SE & Co. KGaA / Schlagwort(e): Fusionen & Übernahmen Fresenius SE & Co. KGaA: Fresenius kündigt Ü...

EC Okays Acquisition Of Merck KGaA's Consumer Health By Procter & Gamble

CINCINNATI (dpa-AFX) - The Darmstadt-based pharmaceutical company Merck KGaA (MKGAY.PK) said that it has received approval from the European Commission to sell its division for over-the-counter me...

Citigroup belässt Merck KGaA auf 'Buy'

Die US-Bank Citigroup hat die Einstufung für Merck KGaA vor einer Investorenveranstaltung in London auf "Buy" belassen. Signale aus den Präsentationen von Wirkstoffkandidaten für die Konferenz der....

docpharm KGaA - HV am 21.07.2018

- die ordentliche Hauptversammlung findet am Samstag, dem 21. Juli 2018 in den Räumen der Gesellschaft, docpharm KGaA, Greschbachstr. 7, 76229 Karlsruhe um 10:30 Uhr statt....

Chemicals competition mars financial picture for Merck KGaA

Shares in Darmstadt-based Merck KGaA slumped almost 5% by mid-afternoon today, as the German chemicals…

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Prenate essential [Sciele Pharma, Inc.]

Prenate Essential™ Rx prenatal vitamin & DHA

Prenate elite [Shionogi Pharma, Inc.]

PRENATE ELITE Tablets Rx

PubMed Articles [4 Associated PubMed Articles listed on BioPortfolio]

Treating MS without continuous immunosuppression: an interview with Luciano Rossetti.

Luciano Rossetti, MD, Executive Vice President, Global Head of R&D at Merck KGaA, Darmstadt, Germany speaks to Laura Dormer, Commissioning Editor Luciano Rossetti, MD, is Executive Vice President, Glo...

The paca that roared: Immediate cumulative semantic interference among newly acquired words.

With 40,000 words in the average vocabulary, how can speakers find the specific words that they want so quickly and easily? Cumulative semantic interference in language production provides a clue: whe...

PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters.

Non-Small Cell Lung Cancer (NSCLC) is the leading cause of cancer death globally, and new immunotherapies developed and under development targeting PD-1/PD-L1 checkpoint inhibition require accurate pa...

The Recipe for Corporate Longevity: From the Perspective of "Managing Innovation".

The elephant is in the room-a metaphorical idiom for an obvious problem or risk that nobody wants to discuss. This abstract is not intended to be a summary, to reveal major findings, or unveil conclus...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects

This study are two-way crossover, open-label, single-dose, fasting, bioequivalence study of Memantinol® (JSC "GEROPHARM", Russia) 20 mg tablets versus Akatinol Memantine® (Merz Pharma Gm...

Study of EMD531444 in Subjects With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Darmstadt, Germany, June 17 2010 - Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome ...

EMD 525797 in Colorectal & Ovarian Cancer Patients With Liver Metastases

This study is intended to test an experimental drug called EMD 525797 (Study Drug). This drug is not yet approved for sale and has only been tested in a small number of people to date (pri...

Companies [30 Associated Companies listed on BioPortfolio]

Sal. Oppenheim jr. & Cie. KGaA

Innovation and tradition – we have always succeeded in combining the two. Since the company‘s founding in 1789, the Cologne private bankers of Sal. Oppenheim have always been a motor for progress ...

Oppenheim Pramerica Fonds Trust GmbH

Nil

Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 40,000 employees work to further develop ...

Alphapharm

Alphapharm is one of Australia's leading pharmaceutical companies. We develop, manufacture, market and distribute prescription medicines and medicines only available at pharmacies. Our speciality is b...

EMD Biosciences, Inc

Together EMD Biosciences and Merck Biosciences are the research reagents group of the Life Science Products division of Merck KGaA. Merck KGaA was founded in 1668 in Darmstadt, Germany, and now has mo...

More Information about "Sal. Oppenheim jr. & Cie. KGaA" on BioPortfolio

We have published hundreds of Sal. Oppenheim jr. & Cie. KGaA news stories on BioPortfolio along with dozens of Sal. Oppenheim jr. & Cie. KGaA Clinical Trials and PubMed Articles about Sal. Oppenheim jr. & Cie. KGaA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sal. Oppenheim jr. & Cie. KGaA Companies in our database. You can also find out about relevant Sal. Oppenheim jr. & Cie. KGaA Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record